Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROTDIP: Raltegravir vs Darunavir/Cobicistat in HIV Patients with CD4 < 200
NCT03842488Phase 4Unknown
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (2 arms). Primary endpoint: Efficacy of RAL vs DRV/cb at 48 weeks. Status: unknown.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03842488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03842488.